Patient P-01365
Synthetic patientNBL-101 · Day 109 · 25–34 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
62%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 50 SC-12 recommended — Supportive Compound SC-12
- Day 51 Patient accepted — Started SC-12 in the companion
- Day 54 GI-04 recommended — GI Support Protocol GI-04
- Day 55 Patient accepted — Started GI-04 in the companion
- Day 57 GI symptom burden −23% vs expected — Supportive Compound SC-12
- Day 63 No meaningful change — GI Support Protocol GI-04
- Day 63 Tolerance state changed — Unstable → Improving
- Day 64 ME-01 recommended — Monitoring Escalation ME-01
- Day 65 Patient accepted — Started ME-01 in the companion
- Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability-23
- Nutritional resilience+12
- Inflammatory activity-10
- Treatment adherence-5
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- Supportive Compound SC-12Day 50Result: symptom burden −23%
- GI Support Protocol GI-04Day 54Result: no meaningful change
- Monitoring Escalation ME-01Day 64Result: deterioration detected before clinical escalation
LIFE OS recommendation
Clinician Review CR-01
72%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 5 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion43.8/100
stable · -0.2 vs previous 14 d
Toxicity
Blood42/100
stable · -0.1 vs previous 14 d
Sleep quality
Wearable30.4/100
stable · +0.1 vs previous 14 d
Energy level
Daily log4/10
stable · -0.1 vs previous 14 d
Stress level
Daily log5.9/10
stable · -0.1 vs previous 14 d
Steps
Wearable3,294
improving · +473 vs previous 14 d
Adherence
Companion45.8 %
stable · +1.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 39 from the failing basin, 48 from restoration.
Would help
- CR-01 Clinician Review100% improved among 8 similar · onset 5 d · confidence 60%
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- NP-02 Dietary Support Protocolalready tried, no meaningful change
- Keep fat lowGI +4.9 next day on high-intake days · n 22
- Keep histamine lowGI +4.3 next day on high-intake days · n 20
- Keep simple carbs lowGI +3.4 next day on high-intake days · n 20
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+4.9detractor · 95%
- Histamine load+4.3detractor · 95%
- Simple carbohydrates+3.4detractor · 95%
- Alcohol+3.2detractor · 68%
- Spicy / capsaicin-1.6no signal · 36%
- Insoluble fibre+1.4no signal · 32%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓40
- DNAFUT2 non-secretor lowers mucosal fucosylation
- WearableSleep 5.9 h, below personal baseline
- Autonomic recovery ↑40
- Wearable3,294 steps/day
- WearableShort sleep window
- Inflammatory signalling ↓25
- BloodInflammatory load index 50
- Drug metabolism and exposure ↑20
- BloodToxicity index 42
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.5 · butyrate capacity 44/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 5.4 h
- Steps
- 2,210
- Resting HR
- 67 bpm
Daily log: GI score 44, nutritional resilience 48, adherence 46.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.